The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Quinoline‐n‐butylcyanoacrylate‐based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease
Abstract
A survey of research activity on nanoparticles (NPs) based on polymeric devices that could cross the blood–brain barrier (BBB) is given along with the presentation of our own data on the development of NPs of n‐butyl‐2‐cyanoacrylate (BCA) for brain delivery to aid the early diagnosis of Alzeimer's disease (AD), a neurodegenerative disorder of the elderly people, the most prevalent form of dementia. Typical data are presented on in vivo detection of amyloid peptides (Aβ) (amyloid plaques) that are used as targets for developing the biological markers for the diagnosis of AD. In order to develop efficient in vivo probes, polymeric n‐butyl‐2‐cyanoacrylate (PBCA) NPs have been prepared and encapsulated with the radio‐labeled amyloid affinity drug 125 I‐clioquinol (CQ, 5‐chloro‐7‐iodo‐8‐hydroxyquinoline) to improve the transport to brain and amyloid plaque retention of 125 I‐CQ using the NPs of PBCA. The 125 I‐CQ discriminately binds to the AD post‐mortem brain tissue homogenates versus control. 125 I‐CQ‐PBCA NPs labeled the Aβ plaques from the AD human post‐mortem frontal cortical sections on paraffin‐fixed slides. Storage phosphor imaging verified preferential uptake by AD brain sections compared to cortical control sections. The 125 I‐CQ‐PBCA NPs crossed the BBB in wild type mouse, giving an increased brain uptake measured in terms of % ID/g i.e., injected dose compared to 125 I‐CQ. Brain retention of 125 I‐CQ‐PBCA NPs was significantly increased in the AD transgenic mice (APP/PS1) and in mice injected with aggregated Aβ42 peptide versus age‐matched wild type controls. The results of this study are verified by in vivo storage phosphor imaging and validated by histopathological staining of plaques and select metal ions, viz. Fe 2+ and Cu 2+. The 125 I‐CQ‐PBCA NPs had more efficient brain entry and rapid clearance in normal mice and enhanced the retention in AD mouse brain demonstrating the ideal in vivo imaging characteristics. The 125 I‐CQ‐PBCA NPs exhibited specificity for Aβ plaques both in vitro and in vivo. This combination offered radio‐iodinated CQ‐PBCA NPs as the promising delivery vehicle for in vivo single photon emission tomography (SPECT) (123 I) or PET (124 I) amyloid imaging agent. The importance of the topic in relation to brain delivery and other similar type of work published in this area are covered to highlight the importance of this research to medical disciplines. WIREs Nanomed Nanobiotechnol 2010 2 35–47 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Self-citationCopper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 4×
“and even FDDNP significantly inhibit the aggregation of Aβ(1-40) peptide in the micromolar range.”
BackgroundInfluentialLong-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443
Metal complexing agents as therapies for Alzheimer’s disease
Bush, A. I. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00120-3 · Cited by 310
Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma
Kontush, A., Berndt, C., Weber, W., Akopyan, V., Arlt, S., Schippling, S., & Beisiegel, U. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00458-5 · Cited by 180
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
“CQ-PBCA NPs can possibly be used as a promising carrier and amyloid imaging agent in vivo using non-invasive methods, single photon emission tomography (SPECT) ((123)I) or PET ((124)I) [126].”
MethodCrossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
“Then the coated PBCA NPs will be taken in by the brain endothelial cells with the help of LDL receptor on these cells through a receptor-mediated endocytosis route [71].”
BackgroundMethodDrug delivery to the central nervous system by polymeric nanoparticles: What do we know?
Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554
Bactericidal activity of silver nanoparticles: A mechanistic review
Anees Ahmad, S., Sachi Das, S., Khatoon, A., Tahir Ansari, M., Afzal, M., Saquib Hasnain, M., & Kumar Nayak, A. (2020) · Materials Science for Energy Technologies · doi:10.1016/j.mset.2020.09.002 · Cited by 541
Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges
Zhang, W., Mehta, A., Tong, Z., Esser, L., & Voelcker, N. H. (2021) · Advanced Science · doi:10.1002/advs.202003937 · Cited by 430
Biomass utilization and production of biofuels from carbon neutral materials
Srivastava, R. K., Shetti, N. P., Reddy, K. R., Kwon, E. E., Nadagouda, M. N., & Aminabhavi, T. M. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2021.116731 · Cited by 370
Self-citationNanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca-Santos, B., Chorilli, M., & Palmira Daflon Gremião, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 308
8-Hydroxyquinolines in medicinal chemistry: A structural perspective
Oliveri, V., & Vecchio, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.007 · Cited by 281
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Theranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
Xu, Julin, G., Yuanjie, Z., Hai, W., Qiushi, R., & Jianghan, C. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17503 · Cited by 69
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Metadata
- Authors
- Kulkarni, P. V., Roney, C. A., Antich, P. P., Bonte, F. J., Raghu, A. V., & Aminabhavi, T. M.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2009-12-14
- Volume
- 2
- Issue
- 1
- Pages
- 35-47
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2036126963
- Cited by
- 159
- References
- 9
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.